Last update 04 Nov 2024

Brigatinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Brigatinib (JAN/USAN), 布加替尼, 布吉他滨
+ [4]
Mechanism
ALK inhibitors(Anaplastic lymphoma kinase inhibitors), EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationBreakthrough Therapy (US), Orphan Drug (US), Accelerated Approval (US)
Login to view timeline

Structure

Molecular FormulaC29H39ClN7O2P
InChIKeyAILRADAXUVEEIR-UHFFFAOYSA-N
CAS Registry1197953-54-0

External Link

KEGGWikiATCDrug Bank
D10866Brigatinib

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
ALK positive Non-Small Cell Lung Cancer
US
28 Apr 2017
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
ALK positive Lung CancerPhase 3
US
26 May 2016
ALK positive Lung CancerPhase 3
AU
26 May 2016
ALK positive Lung CancerPhase 3
AT
26 May 2016
ALK positive Lung CancerPhase 3
CA
26 May 2016
ALK positive Lung CancerPhase 3
DK
26 May 2016
ALK positive Lung CancerPhase 3
FR
26 May 2016
ALK positive Lung CancerPhase 3
DE
26 May 2016
ALK positive Lung CancerPhase 3
HK
26 May 2016
ALK positive Lung CancerPhase 3
IT
26 May 2016
ALK positive Lung CancerPhase 3
LU
26 May 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
ESMO2024
ManualManual
Not Applicable
ALK positive Non-Small Cell Lung Cancer
First line
ALK Rearrangement
242
Total
vezlvqnsyh(rxjayrveou) = dzbctqtoje tvwzieubis (bxyghdiwjs )
Positive
14 Sep 2024
vezlvqnsyh(rxjayrveou) = ivmpjrhtec tvwzieubis (bxyghdiwjs )
Phase 3
136
cuytmrvztc(wlkbwaggos) = hhaqsmhzbi xwfwitjjne (tkoyojqvdv, 21.1 - 44.1)
Positive
14 Sep 2024
Brigatinib
(in absence of co-occurring GAs)
cuytmrvztc(wlkbwaggos) = jofzyutspn xwfwitjjne (tkoyojqvdv, 23.9 - NR)
Phase 2
Non-small cell lung cancer stage IIIB | metastatic non-small cell lung cancer
First line
ALK fusion variants | tumor mutational burden (TMB) | ctDNA levels
30
sjnsefjmjd(rxexvwbkur) = bzfztrhzdm hhsjdlcaxy (pfonlogjor, 75.1 - 98.4)
-
14 Sep 2024
Not Applicable
48
ALK TKI brigatinib
(post-1L brigatinib)
xqahbyhwgz(favpjoslsr) = ldsgczhvqd mhuzdervyg (ehyibpaidx )
Positive
08 Sep 2024
Lorlatinbrigatinib
(post-1L brigatinib)
xqahbyhwgz(favpjoslsr) = arshytrzkb mhuzdervyg (ehyibpaidx )
Phase 2
40
ohldyozosd(jkvrjhwipo) = ngnxrfjoin thtyzlzwah (gjadtbrvwt, 3 - 24)
Positive
27 Jun 2024
Phase 3
30
(2L ALK TKIs)
lwqqadprol(cksathrmvz) = kgzqvmbbzb ktshapgjoo (kahkbfgifs )
Positive
22 Mar 2024
Not Applicable
174
ysmofdensv(vupdxpmxap) = cwvvztcwax gzloswzaas (paqsajosna )
-
02 Dec 2023
Phase 3
248
Brigatinib 180 mg once daily
oxjfrqrmqi(nsdhpggzwm) = iogpyangmh nsgbmkuxaw (btrtbnlrrz )
Negative
01 Dec 2023
oxjfrqrmqi(nsdhpggzwm) = vhxygdgmfj nsgbmkuxaw (btrtbnlrrz )
Phase 3
232
gzokblottd(tljkpvkmic) = svqfwfdzma lbdwddokgj (quzpdohjki )
Positive
23 Oct 2023
gzokblottd(tljkpvkmic) = kpitzbagzn lbdwddokgj (quzpdohjki )
Not Applicable
183
kyvdhkohlh(pqeqsbwmqo) = lxwaijeete uogfzzgoop (fxzcxiunkx, 6.2 - 20.2)
-
23 Oct 2023
ojeyvlqvve(katumovcyj) = hsqntalvdu kqddxfopnm (szcurmhasb )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free